FDA Approves New Drug Daraxonrasib for Advanced Pancreatic Cancer, Doubling Survival

The FDA has granted expedited approval to daraxonrasib (Rasonque), a novel pill for advanced pancreatic cancer. This treatment targets a mutated protein common in over 90% of cases. Clinical trials showed patients on daraxonrasib nearly doubled their median survival time to 13.2 months, compared to 6.7 months with chemotherapy, marking a significant advance against this deadly cancer.